Oncocyte to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics firm, announced participation in key conferences aimed at enhancing patient outcomes. Management will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, and participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15, 2022. Oncocyte focuses on proprietary tests like DetermaRx™ for lung cancer recurrence and DetermaIO™ for immunotherapy response prediction. Their goal is to improve cancer diagnosis and care through personalized insights.

IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that its management team will participate at the following conferences:

• UBS Genomics 2.0 and MedTech Innovations Summit
  Presenting on Thursday, August 11, 2022 at 5:00 p.m. Eastern Time in Dana Point, California. The live audio webcast and replay of the presentation may be accessed for 180 days on the “Investors” section of the company’s website at https://oncocyte.com/.
  

• 7^th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
  Participating on Monday, August 15, 2022
  

About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.

Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com 

Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
Megan.kernan@westwicke.com 

FAQ

What are the upcoming conferences for Oncocyte Corporation in August 2022?

Oncocyte Corporation will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, and will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15, 2022.

What is the focus of Oncocyte's precision diagnostics?

Oncocyte focuses on improving patient outcomes through personalized insights that assist in critical decisions during the patient care journey, particularly in cancer diagnosis and treatment.

What are the key tests developed by Oncocyte Corporation?

Key tests include DetermaRx™, which identifies high-risk lung cancer patients for chemotherapy, and DetermaIO™, which predicts immunotherapy response.

When will Oncocyte's management present at the UBS Summit?

Oncocyte's management will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, at 5:00 p.m. Eastern Time.